Get the Stockscreener App
3.19
1.27%
0.04
After Hours:
3.06
-0.13
-4.08%
Orchestra Biomed Holdings Inc stock is traded at $3.19, with a volume of 250.86K.
It is up +1.27% in the last 24 hours and up +24.12% over the past month.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
See More
Previous Close:
$3.15
Open:
$3.2
24h Volume:
250.86K
Relative Volume:
0.85
Market Cap:
$172.12M
Revenue:
$2.76M
Net Income/Loss:
$-49.12M
P/E Ratio:
-2.1267
EPS:
-1.5
Net Cash Flow:
$-46.21M
1W Performance:
+15.16%
1M Performance:
+24.12%
6M Performance:
+7.05%
1Y Performance:
-37.20%
1-Day Range:
$3.06
$3.2797
1-Week Range:
$2.6616
$3.38
52-Week Range:
$2.20
$6.50
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
Name
Orchestra Biomed Holdings Inc
Sector
Industry
Phone
646-343-9298
Address
150 UNION SQUARE DRIVE, NEW HOPE
Compare OBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
3.19 | 169.96M | 2.76M | -49.12M | -46.21M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-20-25 | Initiated | BTIG Research | Buy |
| Jan-02-25 | Initiated | Barclays | Overweight |
| Aug-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | B. Riley Securities | Buy |
| Jan-19-24 | Initiated | Jefferies | Buy |
| Feb-24-23 | Initiated | Piper Sandler | Overweight |
| Feb-07-23 | Initiated | Chardan Capital Markets | Buy |
View All
Orchestra Biomed Holdings Inc Stock (OBIO) Latest News
Will Orchestra BioMed Holdings Inc. stock beat EPS estimates2025 Market Overview & Verified High Yield Trade Plans - newser.com
Tools to monitor Orchestra BioMed Holdings Inc. recovery probabilityBond Market & AI Powered Market Trend Analysis - newser.com
Applying chart zones and confluence areas to Orchestra BioMed Holdings Inc.Weekly Trend Recap & Reliable Price Breakout Signals - newser.com
Can Orchestra BioMed Holdings Inc. stock reach $100 price targetPortfolio Update Summary & Safe Capital Investment Plans - newser.com
Using data filters to optimize entry into Orchestra BioMed Holdings Inc.Chart Signals & High Win Rate Trade Tips - newser.com
Orchestra BioMed Holdings Inc. stock momentum explained2025 Dividend Review & Community Shared Stock Ideas - newser.com
Orchestra BioMed (NASDAQ:OBIO) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
What does recent volatility data suggest for Orchestra BioMed Holdings Inc.July 2025 Patterns & Risk Controlled Swing Alerts - newser.com
Orchestra BioMed to Showcase Transformative Potential of - GlobeNewswire
Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit - Investing News Network
Orchestra BioMed Presents Comprehensive Data on AVIM Therapy for Hypertensive Heart Disease at Georgia Innovation Summit - Quiver Quantitative
15.6 mmHg Immediate aSBP Drop — Orchestra BioMed AVIM Data; FDA Breakthrough, Oct 10 - Stock Titan
What’s next for Orchestra BioMed Holdings Inc. stock priceJuly 2025 Opening Moves & Advanced Technical Signal Analysis - newser.com
Is Orchestra BioMed Holdings Inc a good long term investmentCapital Gains Strategies & Rapid Portfolio Appreciation - earlytimes.in
Orchestra BioMed Reports Q1 2025 Financial Results and Advances Key Clinical Programs - MSN
Full technical analysis of Orchestra BioMed Holdings Inc. stockTrade Analysis Report & Weekly High Return Stock Forecasts - newser.com
A activityEarnings Summary Report & Weekly High Potential Stock Alerts - newser.com
What institutional flow reveals about Orchestra BioMed Holdings Inc.Long Setup & Consistent Income Trade Ideas - newser.com
Why Orchestra BioMed Holdings Inc. stock is seen as undervaluedPortfolio Gains Summary & Accurate Trade Setup Notifications - newser.com
Evaluating Orchestra BioMed Holdings Inc. with trendline analysis2025 Geopolitical Influence & AI Enhanced Trading Signals - newser.com
Automated trading signals detected on Orchestra BioMed Holdings Inc.Market Movement Recap & High Accuracy Swing Entry Alerts - newser.com
Orchestra BioMed : Corporate Presentation October 2025 - MarketScreener
Published on: 2025-09-29 00:02:42 - newser.com
What analysts say about Orchestra BioMed Holdings Inc stockDividend Stock Watch & Interactive Learning for Better Returns - earlytimes.in
Orchestra Biomed Holdings Hits New 52-Week Low at $2.33 - Markets Mojo
Orchestra Biomed Holdings Hits New 52-Week Low at $2.20 - Markets Mojo
FDA Greenlights Broader Patient Access for AVIM Therapy Trial in Pacemaker Patients - MSN
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Rating of “Buy” by Analysts - Defense World
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Rating of "Buy" by Analysts - MarketBeat
Orchestra Biomed Holdings Inc Stock (OBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Orchestra Biomed Holdings Inc Stock (OBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fain Eric S | Director |
Aug 25 '25 |
Buy |
2.61 |
5,760 |
15,034 |
71,709 |
| Sherman Darren | See Remarks |
Aug 25 '25 |
Buy |
2.62 |
3,000 |
7,860 |
926,837 |
| Hochman David P | See Remarks |
Aug 21 '25 |
Buy |
2.49 |
6,000 |
14,940 |
651,460 |
| Taylor Andrew Lawrence | Chief Financial Officer |
Aug 25 '25 |
Buy |
2.55 |
2,000 |
5,100 |
482,788 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Aug 01 '25 |
Buy |
2.75 |
700,000 |
1,925,000 |
5,292,556 |
| Hochman David P | See Remarks |
Aug 04 '25 |
Buy |
2.75 |
20,000 |
55,000 |
349,331 |
| Fain Eric S | Director |
Jun 26 '25 |
Sale |
3.05 |
2,683 |
8,183 |
50,949 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):